PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $811,391 | -21.7% | 78,244 | +8.1% | 0.00% | – |
Q2 2023 | $1,036,511 | +54.9% | 72,382 | -22.7% | 0.00% | – |
Q1 2023 | $669,003 | -13.8% | 93,698 | +35.4% | 0.00% | – |
Q4 2022 | $776,290 | -24.3% | 69,188 | -25.1% | 0.00% | – |
Q3 2022 | $1,025,000 | +11.5% | 92,430 | -15.1% | 0.00% | – |
Q2 2022 | $919,000 | -20.2% | 108,862 | +28.7% | 0.00% | – |
Q1 2022 | $1,151,000 | -58.0% | 84,600 | -39.2% | 0.00% | – |
Q4 2021 | $2,738,000 | +219.5% | 139,168 | +420.6% | 0.00% | – |
Q3 2021 | $857,000 | -4.4% | 26,733 | +0.9% | 0.00% | – |
Q2 2021 | $896,000 | +44700.0% | 26,492 | +44801.7% | 0.00% | – |
Q1 2021 | $2,000 | -99.2% | 59 | -99.3% | 0.00% | – |
Q4 2020 | $264,000 | +560.0% | 7,933 | +624.5% | 0.00% | – |
Q3 2020 | $40,000 | -63.6% | 1,095 | -67.1% | 0.00% | – |
Q2 2020 | $110,000 | +423.8% | 3,332 | +300.5% | 0.00% | – |
Q1 2020 | $21,000 | -95.3% | 832 | -94.2% | 0.00% | – |
Q4 2019 | $450,000 | – | 14,441 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |